Cindy is passionate about innovation to make genetic and multi-omic technologies easier and cheaper to measure. She sees such innovation as pivotal to lower the barrier of entry for implementing scalable, reproducible solutions advancing individualized medicine and health equity. In over 14 years at Illumina and together with customers, she helped develop solutions to advance the understanding of genetic risk and holds several USDA Excellence in Technology Transfer awards for her work leading Illumina’s Consortia Program. She joined Olink in 2020 soon after the launch of the Explore Platform that leverages next generation sequencing as a high throughput proteomic readout. Ask her about how high throughput proteomics are helping translate the impact our genetics has on more real time health.
Track Chair: Cindy Lawley, Olink